Federal Trade Commission accuses three drug middlemen of inflating insulin prices
In a lawsuit, the FTC accused Optum Rx, Caremark and Express Scripts of creating "a broken rebate system that inflated insulin drug prices, boosting PBM (prescription drug benefit managers) profits at the expense of vulnerable patients.
A Federal Trade Commission (FTC) report found that social and video streaming services pose serious privacy risks, especially ...
A federal judge in Virginia found Thursday that former George Mason University's Antonin Scalia Law School professor Joshua ...
The federal government is suing some pharmacy benefit managers over a system of drug rebates that regulators say has made the ...
California courts were home to the most federal trade secrets litigation over the past three years, according to a report ...
Last month, the Federal Trade Commission (FTC) and U.S. Department of Justice (DOJ) jointly hosted a public meeting of the interagency “Strike ...
Three companies that process about 80% of prescriptions in the United States — Caremark, Express Scripts and OptumRx — have ...
On Monday, fashion icon Michael Kors testified in an antitrust trial in Manhattan as a Federal Trade Commission lawsuit filed ...
Under the FOCAL plan, federal agencies have been urged to prioritize asset management, vulnerability management, defensible ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback